187 related articles for article (PubMed ID: 28129624)
1. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
Su C; Zhang P; Liu J; Cao Y
Biomed Pharmacother; 2017 Apr; 88():521-528. PubMed ID: 28129624
[TBL] [Abstract][Full Text] [Related]
2. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
[TBL] [Abstract][Full Text] [Related]
3. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Yang A; Li MY; Zhang ZH; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Zuo HX; Ma J; Jin X
J Ethnopharmacol; 2021 Jun; 273():113598. PubMed ID: 33220359
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent.
Gong YQ; Fan Y; Wu DZ; Yang H; Hu ZB; Wang ZT
Eur J Cancer; 2004 Jul; 40(10):1554-65. PubMed ID: 15196540
[TBL] [Abstract][Full Text] [Related]
5. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.
Chen J; Liu J; Xu B; Cao Y; Liang X; Wu F; Shen X; Ma X; Liu J
Toxicol Appl Pharmacol; 2022 Mar; 438():115911. PubMed ID: 35143806
[TBL] [Abstract][Full Text] [Related]
6. Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo.
Zhang HQ; Xie XF; Li GM; Chen JR; Li MT; Xu X; Xiong QY; Chen GR; Yin YP; Peng F; Chen Y; Peng C
Phytother Res; 2021 Aug; 35(8):4511-4525. PubMed ID: 34236105
[TBL] [Abstract][Full Text] [Related]
7. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Wei L; Zhu S; Li M; Li F; Wei F; Liu J; Ren X
Front Immunol; 2018; 9():724. PubMed ID: 29719533
[TBL] [Abstract][Full Text] [Related]
8. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
9. Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model.
Luo B; Que ZJ; Zhou ZY; Wang Q; Dong CS; Jiang Y; Hu B; Shi H; Jin Y; Liu JW; Li HG; Wang L; Tian JH
J Integr Med; 2018 Jul; 16(4):283-289. PubMed ID: 29752140
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
11. Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells.
Gong Y; Fan Y; Liu L; Wu D; Chang Z; Wang Z
In Vivo; 2004; 18(2):223-8. PubMed ID: 15113050
[TBL] [Abstract][Full Text] [Related]
12. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis.
Chen P; Wu Q; Feng J; Yan L; Sun Y; Liu S; Xiang Y; Zhang M; Pan T; Chen X; Duan T; Zhai L; Zhai B; Wang W; Zhang R; Chen B; Han X; Li Y; Chen L; Liu Y; Huang X; Jin T; Zhang W; Luo H; Chen X; Li Y; Li Q; Li G; Zhang Q; Zhuo L; Yang Z; Tang H; Xie T; Ouyang X; Sui X
Signal Transduct Target Ther; 2020 May; 5(1):51. PubMed ID: 32382060
[TBL] [Abstract][Full Text] [Related]
13. Erianin inhibits high glucose-induced retinal angiogenesis via blocking ERK1/2-regulated HIF-1α-VEGF/VEGFR2 signaling pathway.
Yu Z; Zhang T; Gong C; Sheng Y; Lu B; Zhou L; Ji L; Wang Z
Sci Rep; 2016 Sep; 6():34306. PubMed ID: 27678303
[TBL] [Abstract][Full Text] [Related]
14. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
[TBL] [Abstract][Full Text] [Related]
15. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.
Nonaka H; Saga Y; Fujiwara H; Akimoto H; Yamada A; Kagawa S; Takei Y; Machida S; Takikawa O; Suzuki M
Int J Oncol; 2011 Jan; 38(1):113-20. PubMed ID: 21109932
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
18. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
19. Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.
Wang Y; Fan X; Wu X
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32530032
[TBL] [Abstract][Full Text] [Related]
20. Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice.
Huh JE; Baek YH; Lee MH; Choi DY; Park DS; Lee JD
Cancer Lett; 2010 Jun; 292(1):98-110. PubMed ID: 20188461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
